|  |  |
| --- | --- |
| **ID** |  |
| **Name** |  |
| **Gender** |  |
| **DoB** |  |
| **DoDiag** |  |
| **Age** | calculated |
| **Date of last contact** |  |
| **Status** |  |
| **Survival from diagnosis** | calculated |
| **Dead 3 mos** | 0=no; 1=yes |
| **Dead 6 mos** | 0=no; 1=yes |
| **Dead 9 mos** | 0=no; 1=yes |
| **Dead 12 mos** | 0=no; 1=yes |
| **Heart** | 0=no; 1=yes |
| **Kidney** | 0=no; 1=yes |
| **Liver** | 0=no; 1=yes |
| **Soft tissues** | 0=no; 1=yes |
| **PNS** | 0=no; 1=yes |
| **ANS** | 0=no; 1=yes |
| **GI** | 0=no; 1=yes |
| **Other** |  |
| **Number of organs** | calculated |
| **PS (ECOG)** |  |
| **PS ≥2** | 0=no; 1=yes |
| **NYHA 3 or 4** | 0=no; 1=yes |
| **NYHA class** |  |
| **Type of treatment** |  |
| **Bortezomib** | 0=no; 1=yes |
| **Dex dose reduction** | 0=no; 1=yes |
| **Date of treatment initiation** |  |
| **SAE type** |  |
| **SAE** | 0=no; 1=yes |
| **Date of first response** |  |
| **Time to resp** | calculated |
| **Organ response** | 0=no; 1=yes |
| **Organ that responded** |  |
| **CR by IFE** |  |
| **Cardiac resp** |  |
| **Renal resp** |  |
| **Date of best response** |  |
| **SURV from resp** | calculated |
| **Time to best response** | calculated |
| **N of cycles** |  |
| **NT-proBNP** |  |
| **NT-proBNP >332** | 0=no; 1=yes |
| **NT-proBNP >1800** | 0=no; 1=yes |
| **NT-proBNP >650** | 0=no; 1=yes |
| **Mayo Stage** |  |
| **Revised Mayo Stage** |  |
| **NT-proBNP (best resp)** |  |
| **Delta NT-proBNP abs** | calculated |
| **Delta NT-proBNP perc** | calculated |
| **NT-proBNP resp** | 0=no; 1=yes |
| **NT-proBNP progr** | 0=no; 1=yes |
| **NT-proBNP R or P** | 1=response; 2=stable; 3=progressed |
| **BNP (ng/L)** |  |
| **BNP (best resp)** |  |
| **DeltaBNPabs** | calculated |
| **DeltaBNPper** | calculated |
| **BNP RP** | 1=response; 2=stable; 3=progressed |
| **cTnI** |  |
| **cTnI >0,07** |  |
| **cTnI >0,1** |  |
| **cTnI (best resp)** |  |
| **Delta cTnI %** | calculated |
| **cTnI progression** | 0=no; 1=yes |
| **Repetitive ventricular arrhythmia (Holter)** | 0=no; 1=yes |
| **IVS (mm)** |  |
| **PW (mm)** |  |
| **mLVW (mm)** | calculated |
| **EF (%)** |  |
| **IVS (3 mos post therapy)** |  |
| **PW (3 mos post therapy)** |  |
| **mLVW (3 mos post therapy)** | calculated |
| **EF (3 mos post therapy)** |  |
| **s.creat (mg/dL)** |  |
| **u.prot (g/24h)** |  |
| **eGFR (by MDRD)** | calculated |
| **CKD stage** |  |
| **s. creat at 3 mos** |  |
| **delta creat abs** |  |
| **delta creat >0,5 mg/dL** | 0=no; 1=yes |
| **eGFR at 3 mos** | calculated |
| **delta eGFR perc** | calculated |
| **delta eGFR >25%** | 0=no; 1=yes |
| **Profgression of renal failure** | 0=no; 1=yes (both >25% increase in eGFR and >0,5 mg/dL increase inn s. creat) |
| **u.prot at 3 mos** |  |
| **delta uprot perc** |  |
| **Renal RESP** | 0=no; 1=yes |
| **alk phosph (U/L)** |  |
| **Alk phosph >1,5 times upper limit of normal** | 0=no; 1=yes |
| **alk phosph (3 mos post therapy)** |  |
| **delta ALP perc** | calculated |
| **Liver resp** | 0=no; 1=yes |
| **BMPC %** |  |
| **MC type (G, A, M, D, LC)** |  |
| **MC conc. (g/L)** |  |
| **MC conc. >10 g/L (1=y, 0=n)** |  |
| **LC type (K, L)** |  |
| **iFLC** |  |
| **dFLC** |  |
| **dFLC >50 mg/L** | 0=no; 1=yes |
| **dFLC >180 mg/L** | 0=no; 1=yes |
| **FLC k (mg/L)** |  |
| **FLC l (mg/L)** |  |
| **k/l (ratio)** |  |
| **iFLC post** |  |
| **dFLC post** |  |
| **dFLC rem perc** |  |
| **HEM RESP** | 1=CR; 2=VGPR; 3=PR; 4=NR |
| **Any Hem Resp** | 0=no; 1=yes |
| **FLC k (3 mos post therapy)** |  |
| **FLC l (3 mos post therapy)** |  |
| **k/l (3 mos post therapy)** |  |
| **2nd line tp type** |  |
| **Date of 2nd line therapy initiation** |  |
| **Time to 2nd line** | calculated |
| **Ref/Rel** | refractory=0; relapsed=1 |
| **Response to 2nd line** | 1=CR; 2=VGPR; 3=PR; 4=NR |
| **Organ resp to 2nd line** | 0=no; 1=yes |
| **Responding organ** |  |
| **Progression (0=no;1=yes)** |  |
| **PFS** | calculated |
| **date of progression** |  |
| **Survival from progression** | calculated |